Scancell Holdings plc (LON:SCLP – Get Free Report)’s stock price traded down 7.7% during trading on Thursday . The company traded as low as GBX 18.18 and last traded at GBX 18.92. 3,734,724 shares traded hands during mid-day trading, an increase of 85% from the average session volume of 2,019,624 shares. The stock had previously closed at GBX 20.50.
Scancell Price Performance
The company has a current ratio of 0.56, a quick ratio of 13.01 and a debt-to-equity ratio of -193.29. The company has a market cap of £196.35 million, a P/E ratio of -34.40 and a beta of 0.57. The business’s fifty day moving average is GBX 17.46 and its 200 day moving average is GBX 13.70.
About Scancell
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Further Reading
- Five stocks we like better than Scancell
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
